1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1620
  5. Art Unit 1621
  6. Examiner Aulakh

Examiner Aulakh Charanjit

1621-AULAKH-CHARANJIT

Employment Information

Art Unit:1621 — Drug, bio-affecting and body treating compositions
Group:1620 — Biomedicinal Chemistry
Classes: 514 — Drug, bio-affecting and body treating compositions
546 — Organic compounds -- part of the class 532-570 series
549 — Organic compounds -- part of the class 532-570 series
544 — Organic compounds -- part of the class 532-570 series
548 — Organic compounds -- part of the class 532-570 series
540 — Organic compounds -- part of the class 532-570 series
257 — Active solid-state devices (e.g., transistors, solid-state diodes)
424 — Drug, bio-affecting and body treating compositions
428 — Stock material or miscellaneous articles
560 — Organic compounds -- part of the class 532-570 series
Phone:(571) 272-0678
Email:charanjit.aulakh@uspto.gov
Location:VA 22314
Title:Pat Examnr Gen Chem
Service:30 years
Grade:GS-14

Grant Rate and Difficulty Ranking

34
3-Year Grant rate: 85% over 754 cases
Difficulty: Easier
Difficulty Percentile: 34th

With Examiner Aulakh, you have a 85% chance of getting an issued patent by 3 years after the first office action. Examiner Aulakh is an easier examiner and in the 34th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Aulakh, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1621

Examiner Aulakh's grant rate is higher than that of Art Unit 1621 and higher than that of the USPTO.

Average Office Actions Per Grant
Examiner Aulakh 1.2
Art Unit 1621 1.2

Interview Benefit

Grant Rate without Interview

Examiner Aulakh has granted 581 of 688 cases without any applicant-requested interviews for a grant rate of 84%.

Grant Rate with Interview

Examiner Aulakh has granted 57 of 66 cases with at least one applicant-requested interview for a grant rate of 86%.

Interview Benefit

With Examiner Aulakh, conducting an interview increases your chance of getting a patent granted by 2%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18248841 Benzalkonium Chloride Foruse In Treating Conjunctivitis And/or Covid-19 Rejection information available with a Premium Stats subscription. See our pricing. Patented View
18027246 Salt Of Benzothiazole Compound, And Crystal Form And Use Thereof Patented View
17760077 Compound, Luminescent Material, Delayed Fluorescent Material, And Organic Optical Device Patented View
18008611 Sterilized Formulations Abandoned View
18636240 Bupropion As A Modulator Of Drug Activity Patented View
17927272 Methods Of Treating Cftr Related Diseases And Disorders Abandoned View
17906541 Kappa Opiod Receptor Antagonists For Treating Pain-Related Sleep Disorders Patented View
18040192 Trex1 Inhibitors And Uses Thereof Abandoned View
17921905 Thieno Pyrimidines As Ferroportin Inhibitors Patented View
18048340 1,5-Dihydro-2,4-Benzodiazepine-3-One Derivative And Application Thereof Patented View
17922072 5-Chloro-4-Hydroxy-1-Methyl-2-Oxo-N-Phenyl-Quinoline-3-Carboxamide Potassium Salt For Treating Inflammatory Bowel Diseases Abandoned View
18274290 Pyrimidine Derivative Patented View
17919212 Forms And Compositions Of Inhibitors Of Plasma Kallikrein Abandoned View
18376441 Lighting Device Abandoned View
18731285 Heteroaryl Derivative Compounds, And Uses Thereof Patented View
18342397 Leveler And Electroplating Composition For Filling Via Hole Patented View
17743018 Iridium Phosphorescent Material, Preparation Method Therefor, And Photophysical Properties Thereof Abandoned View
19196683 Compositions And Methods For Inhibition Of Ras Patented View
18414371 Heteroaryl Derivative Compounds, And Uses Thereof Patented View
18012768 Anticoccidial Agent And Method For Using The Same Patented View
18018438 N'-(2-Chloro-6-Methylbenzoyl)-4-Methyl-3-[2-(3-Quinolyl)ethynyl]-Benzohydrazide For Treatment Of Alzheimer's Disease Abandoned View
17919420 Use Of Psilocybin In The Treatment Of Neurological Brain Injury And Migraines Abandoned View
18669184 Tricyclic Janus Kinase 1 Inhibitors, And Compositions And Methods Thereof Patented View
17907647 Inhibitors Of Antigen Presentation By Hla-Dr Patented View
17633072 Compositions And Methods For The Treatment Of Pain And Dependance Disorders Patented View
17791983 Novel Pyrazole Derivative Patented View
18419007 Metal Assisted Delayed Fluorescent Emitters For Organic Light-Emitting Diodes Patented View
17777588 Triazatricycle Compounds For The Treatment Of Autoimmune Disease Patented View
18414720 Organic Light-Emitting Device And Organometallic Compound Patented View
18058549 Carm1 Inhibitors And Uses Thereof Abandoned View
19053093 Method Of Converting Mitragynine To 7-Hydroxymitragynine Patented View
18375817 Diagnostic Opioid Taper Regimen Abandoned View
17914826 Factor Xi Activation Inhibitors Patented View
18980700 Therapeutics For The Degradation Of Mutant Braf Patented View
17920890 Cbp/ep300 Inhibitor And Use Thereof Patented View
17636909 Tetradentate Ligands, Gold(Iii) Complexes, Preparation Method And Use Thereof Patented View
17759341 Preparation Of Semicarbazide-Sensitive Amine Oxidase Inhibitor And Use Thereof Patented View
17906109 Method Of Treating Covid-19 Patented View
17594214 Novel Oxadiazole Compounds For Controlling Or Preventing Phytopathogenic Fungi Patented View
17922188 Phenylpropionamide Compound And Use Thereof Patented View
18648027 Combination Therapy For Use In Treating Retroviral Infections Abandoned View
17884305 Polysubunit Opioid Prodrugs Resistant To Overdose And Abuse Abandoned View
18664689 Method Of Converting Mitragynine To 7-Hydroxymitragynine Patented View
17792685 3-Benzoyl-1h-Pyrrolo[2,3-B]pyridine Derivatives As Mkk4 Inhibitors For Treating Liver Diseases Patented View
17785791 Spirocyclic Piperidine Melanocortin Subtype-2 Receptor (Mc2r) Antagonists And Uses Thereof Patented View
17483959 Heterocyclic Compounds As Immunomodulators Patented View
18295667 Novel Compounds For The Treatment, Alleviation Or Prevention Of Disorders Associated With Tau Aggregates Abandoned View
18406817 Inhibiting (Alpha-V)(Beta-6) Integrin Patented View
17612034 Processes And Intermediates For Preparing A Btk Inhibitor Patented View
18431267 Therapeutic Compounds Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.